Denosumab

Active pharmaceutical substance formulated in Jan Aushadhi generic products for Pain, Fever & Arthritis treatment.

🧴 Clinical Application

Administer by SUBCUTANEOUS (SC) injection only (60 mg once every 6 months) into the upper arm, upper thigh, or abdomen by a healthcare professional. All patients MUST receive daily calcium (at least 1000 mg) and vitamin D (at least 400-800 IU) supplementation to prevent severe hypocalcemia. NEVER interrupt or delay doses without initiating alternative antiresorptive therapy.

⚠️ Side Effects

Common: Back pain, pain in extremities, musculoskeletal pain, hypercholesterolemia, cystitis, nasopharyngitis. Rare/Severe: Severe hypocalcemia (especially in CKD patients), Osteonecrosis of the Jaw (ONJ), atypical subtrochanteric femoral fractures, serious infections (cellulitis), and rebound multiple vertebral fractures upon drug discontinuation.

🛡️ Safety Warnings

Black Box Warning: Severe, potentially fatal hypocalcemia in patients with advanced chronic kidney disease (CKD stage 4-5/dialysis); check calcium levels prior to each dose and correct hypocalcemia. CRITICAL REBOUND PHENOMENON: Discontinuing or delaying denosumab causes a rapid, massive rebound in bone resorption (bone turnover surge), resulting in rapid bone loss and multiple spontaneous vertebral fractures; transition to an IV bisphosphonate (zoledronic acid) is mandatory if denosumab is stopped. Dental exam recommended prior to therapy.